| Literature DB >> 22783143 |
Ganna Mykhailivna Shayakhmetova1, Larysa Borysivna Bondarenko, Valentina Mykolaivna Kovalenko.
Abstract
The necessity to minimize adverse effects of tuberculosis chemotherapy requires a comprehensive evaluation of the effects of antituberculosis drugs on the reproductive system and testicular cell macromolecules. The epidemiological situation of tuberculosis in Central and Eastern Europe is getting worse. Data on adverse effects of antituberculosis drugs are scare concerning particularly their effects on the reproductive system. The aim of the present study was to investigate the potential effect of ethambutol, rifampicin, isoniazid and pyrazinamide co-administration on lipid peroxidation, glutathione content and protein SH-groups, DNA fragmentation levels, the reproductive capacity of Wistar male rats and the antenatal development of their posterity. The rats (150-170 g) were divided into two groups: group I - received antituberculosis drugs suspended in 1% starch gel per os: ethambutol - 155 mg/kg b.w./day, rifampicin - 74.4 mg/kg b.w./day, isoniazid - 62 mg/kg b.w./day, pyrazinamide - 217 mg/kg b.w./day, group II (control) - received only starch gel in corresponding volumes. The contents of TBA-active compounds, glutathione and protein SH-groups in testis and sperm were determined spectrophotometrically, the DNA-fragmentation was determined using an UV transilluminator (BIORAD, USA), reproductive system indices were measured by standard methods. The co-administration of therapeutic doses of ethambutol, isoniazid, rifampicin and pyrazinamide to male rats during the period of spermatogenesis caused an increase in the rate of thiobarbituric acid reactive substances formation in testis and sperm, decrease of testis glutathione and protein SH-group contents, significant changes in DNA fragmentation, fatal decrease of male fertilizing capacity and fertility, and increase of pre- and post-implantation embryo lethality. The changes in reproductive indices could be the result of direct or indirect effects of one or more drugs investigated.Entities:
Keywords: DNA-fragmentation; antituberculosis drugs; male reproductive capacity; rat; testis
Year: 2012 PMID: 22783143 PMCID: PMC3389503 DOI: 10.2478/v10102-012-0002-9
Source DB: PubMed Journal: Interdiscip Toxicol ISSN: 1337-6853
The rate of ascorbate induced formation of TBARS in male rats testis homogenate and epididymal suspension of spermatozoids, nmoles/min × mg of protein (M ± S.E.M., n=12).
| Tissue | ||
|---|---|---|
| Group | testis | epididymal suspension of spermatozoids |
| Antituberculosis drugs | 0.302±0.031 | 0.162±0.006 |
| Control | 0.259±0.02 | 0.100±0.006 |
M ± S.E.M. – mean ± standard error of the mean
p<0.05 statistically significant in comparison with control
Contents of rat testis glutathione and protein SH-groups with combined administration of antituberculosis drugs, nmoles/mg of protein (M ± S.E.M., n =12).
| Group | Contents of glutathione | Contents of protein SH-groups nmoles/mg of protein |
|---|---|---|
| Antituberculosis drugs | 21.25±1.52 | 45.44±4.76 |
| Control | 26.32±0.91 | 58.41±3.64 |
M ± S.E.M. – mean ± standard error of the mean
p<0.05 statistically significant in comparison with control
Figure 1Levels of DNA fragmentation in rat testis (Mr – marker; lane 1 – control group; lane 2 – antituberculosis drugs co-administration). Analysis was carried out using the Quantity One Software.
Rat male fertility index with combined administration of antituberculosis drugs.
| Group of males | Number of mated females | Number of pregnant females | Fertility index, % |
|---|---|---|---|
| Antituberculosis drugs | 24 | 4 | 17 |
| Control | 24 | 22 | 91.7 |
Fertility and embryogenesis parameters on day 20 of gestation – day of mating intact rat females with male rats treated by combined administration antituberculosis drugs.
| Male group indices | Control | Antituberculosis drugs |
|---|---|---|
| Number of pregnant females | 22 | 4 |
| Total number of corpora lutea | 244 | 75 |
| Number of corpora lutea per one female, M ± S.E.M. | 11.09±0.37 | 18.75±3.59 |
| Total number of implantation sites | 219 | 26 |
| Number of implantation sites per one female, M ± S.E.M. | 9.95±0.59 | 6.50±3.33 |
| Preimplantational loss, abs/% | 18 / 10.25 | 48 / 65.3 |
| Preimplantational loss per one female, M ± S.E.M. | 0.82±0.32 | 12.0±3.89 |
| Postimplantational loss, abs/% | 9 / 4.1 | 20 / 76.9 |
| Postimplantational loss per one female, M ± S.E.M. | 0.41±0.15 | 5.0±3.72 |
| Total number of living fetuses, abs/% | 217 / 99.09 | 7 / 27 |
| Number of living fetuses per one female, M ± S.E.M. | 9.08±0.52 | 1.75±1.43 |
M ± S.E.M. – mean ± standard error of the mean
p<0.05 statistically significant in comparison with control
Preimplantational loss was calculated as: % preimplantational loss = [(number of corpora lutea – number of implantation sites) / number of corpora lutea] × 100
Postimplantational loss was calculated as: % postimplantational loss = (number of lost fetuses / number of implantation sites) × 100